ライフサイエンスコーパス: viral hepatitis

1 r other diseases, including tuberculosis and viral hepatitis.

2 was critical for priming T cell responses in viral hepatitis.

3 s (HDV) causes the most severe form of human viral hepatitis.

4 ponents of the liver parenchyma during acute viral hepatitis.

5 liver disease, hepatocellular carcinoma, and viral hepatitis.

6 tor and a hepatoprotective cytokine in acute viral hepatitis.

7 lications of these effects as they relate to viral hepatitis.

8 therapeutic candidate for the management of viral hepatitis.

9 temporally restricted to the acute phase of viral hepatitis.

10 mmune responses to viral antigens in chronic viral hepatitis.

11 osis in the early and intermediate stages of viral hepatitis.

12 delta virus (HDV) is the most severe form of viral hepatitis.

13 tocellular carcinoma with or without chronic viral hepatitis.

14 pffer cells and hepatocytes of patients with viral hepatitis.

15 targets for this most severe form of chronic viral hepatitis.

16 clinical features are compatible with acute viral hepatitis.

17 ) to those from source patients with chronic viral hepatitis.

18 e (ALT) activity among 11,821 adults without viral hepatitis.

19 have great therapeutic potential in chronic viral hepatitis.

20 reviously been correlated with resistance to viral hepatitis.

21 eck and epidemic infection, including recent viral hepatitis.

22 st hepatitis C virus (HCV), a major cause of viral hepatitis.

23 year will help us fine tune the treatment of viral hepatitis.

24 lly all of the liver disease associated with viral hepatitis.

25 nce of liver infections, such as malaria and viral hepatitis.

26 rated the potential for the immunotherapy of viral hepatitis.

27 to-date summary of important developments in viral hepatitis.

28 cal and histopathological changes typical of viral hepatitis.

29 s) and organ damage in mouse models of acute viral hepatitis.

30 or the most severe form of acute and chronic viral hepatitis.

31 ents in the Sentinel Counties Study of Acute Viral Hepatitis.

32 ciated with steatosis or steatohepatitis and viral hepatitis.

33 lay an important role in the pathogenesis of viral hepatitis.

34 e patterns in 3 of 4 patients with confirmed viral hepatitis.

35 Hepatitis C virus (HCV) is a major cause of viral hepatitis.

36 ficantly enhance the carcinogenic effects of viral hepatitis.

37 elopment of novel therapeutic strategies for viral hepatitis.

38 rently the only well-established therapy for viral hepatitis.

39 erally does not develop recurrent disease or viral hepatitis.

40 inotransferases, clinically resembling acute viral hepatitis.

41 of excess alcohol consumption, obesity, and viral hepatitis.

42 thologies such as cholestasis, steatosis and viral hepatitis.

43 nts can build their local strategies towards viral hepatitis.

44 fection typically causes self-limiting acute viral hepatitis.

45 ical features resembling those seen in human viral hepatitis.

46 ere stratified by the presence or absence of viral hepatitis.

47 eased in humans and chimpanzees with chronic viral hepatitis.

48 target cells for future treatment options in viral hepatitis.

49 inant IFN-alpha for the treatment of chronic viral hepatitis.

50 it contributes to the pathogenesis of acute viral hepatitis.

51 (HCV), this has not been evaluated in acute viral hepatitis.

52 on diagnoses were latent tuberculosis (22%), viral hepatitis (17%), active tuberculosis (10%), human

53 0 with acetaminophen-related injury, 26 with viral hepatitis, 19 with ischemic injury, and 62 others.

54 e draft WHO Global Health Sector Strategy on Viral Hepatitis 2016-21 provides a solid framework upon

55 SL metabolites in 406 patients with chronic viral hepatitis, 203 infected with genotype 1 hepatitis

56 276 patients with chronic liver disease (42% viral hepatitis, 46% nonalcoholic fatty liver disease [N

57 ificantly greater among persons with chronic viral hepatitis (69% of cases) and those prescribed conc

58 lies on exclusion of other causes, including viral hepatitis A, B, and C.

59 Chronic viral hepatitis accounts for >80% of liver-related morta

60 Health and Human Services (HHS) published a viral hepatitis action plan that guides response to the

61 Viral hepatitis affects millions of people worldwide, ma

62 Studies on viral hepatitis after liver transplantation again focuse

63 rs indicate the need for improved control of viral hepatitis after solid organ transplantation.

64 nding preexisting liver illnesses, including viral hepatitis, alcohol abuse, or metabolic disease.

65 of liver disease: (1) hepatocellular (e.g., viral hepatitis, alcohol-related), (2) cholestatic (e.g.

66 95 patients hospitalized with either chronic viral hepatitis, alcoholism, cirrhosis, or any combinati

67 epatocellular carcinoma was 34.4 for chronic viral hepatitis alone, 2.4 for alcoholism alone, and 40.

68 virus, generally causes self-limiting acute viral hepatitis, although chronic HEV infection has rece

69 es histological features with those of human viral hepatitis, although the specific aetiological agen

70 rovements in vaccines and treatments against viral hepatitis, an improved understanding of the burden

71 Chronic viral hepatitis and alcohol remain leading causes of cir

72 ound of chronic liver inflammation caused by viral hepatitis and alcoholic or nonalcoholic steatohepa

73 ve study has analyzed simultaneously chronic viral hepatitis and alcoholism as risk factors for liver

74 epatocellular carcinoma was 27.3 for chronic viral hepatitis and alcoholism, 118.5 for chronic viral

75 Furthermore, the contributions of viral hepatitis and ALD to CLD mortality may be underest

76 al mechanism for the death of hepatocytes in viral hepatitis and also in endothelial injury in the co

77 veral clinical conditions, including chronic viral hepatitis and chronic myeloproliferative and lymph

78 asive screening for HCC in populations where viral hepatitis and cirrhosis are prevalent.

79 hepatitis and alcoholism, 118.5 for chronic viral hepatitis and cirrhosis, 22.4 for alcoholism and c

80 ppression would lessen the risk of recurrent viral hepatitis and eliminate much of the morbidity asso

81 his study describes the relationship between viral hepatitis and HCC in New York City (NYC).

82 ated in clinical trials for the treatment of viral hepatitis and liver cancer.

83 widely used interferon for the treatment of viral hepatitis and malignancies, in primary cells (peri

84 is widely used for the treatment of chronic viral hepatitis and malignancies.

85 Individuals with chronic viral hepatitis and other forms of liver disease are at

86 After viral hepatitis and recent drug exposure were excluded,

87 AdCre developed a relatively mild course of viral hepatitis and recovered spontaneously.

88 e morbidity and mortality related to chronic viral hepatitis and released its findings in a report.

89 sion of the stop cassette led to a transient viral hepatitis and resulted in multinodular tumorigenes

90 vices can increase the success of preventing viral hepatitis and the effectiveness of hepatitis treat

91 ay an important role in both defense against viral hepatitis and the pathogenesis of other liver dise

92 V and other infectious complications such as viral hepatitis and tuberculosis, and many non-HIV-assoc

93 idity and mortality worldwide due to chronic viral hepatitis and, more recently, from fatty liver dis

94 developed clinical liver disease because of viral hepatitis, and all patients alive (n=21) at follow

95 nsplant immunology, infection, inflammation, viral hepatitis, and fibrogenesis.

96 o estimate morbidity and mortality for acute viral hepatitis, and for cirrhosis and liver cancer caus

97 liver diagnoses (eg, hepatorenal syndrome), viral hepatitis, and hepatobiliary cancers.

98 in the livers of patients with autoimmune or viral hepatitis, and of mice during concanavalin A (Con

99 f its comorbidities, including tuberculosis, viral hepatitis, and renal and cardiovascular disease.

100 s include gallstones, hepatic sequestration, viral hepatitis, and sickle cell intrahepatic cholestasi

101 have a lack of knowledge and awareness about viral hepatitis, and that there is a gap between medical

102 The enormous health loss attributable to viral hepatitis, and the availability of effective vacci

103 Cirrhosis, viral hepatitis, and toxic drug effects can all trigger

104 es, for the prevention and treatment of HIV, viral hepatitis, and tuberculosis.

105 a range of infectious diseases such as HIV, viral hepatitis, and tuberculosis.

106 discrimination against people infected with viral hepatitis; and financial barriers to treatment and

107 nch National Agency for Research on AIDS and Viral Hepatitis (ANRS) CO13 HEPAVIH cohort initiating an

108 ated liver diseases including autoimmune and viral hepatitis are a major health problem worldwide.

109 FPAs during acute viral hepatitis are associated with higher IgM levels an

110 HIV and viral hepatitis are independently associated with an inc

111 f persons at risk for or who are living with viral hepatitis are not aware of the risks, have not bee

112 The pathogenic mechanisms involved in viral hepatitis are not completely understood.

113 The majority of the patients had viral hepatitis as the underlying liver disease (100% in

114 is virus, a murine coronavirus used to model viral hepatitis as well as other human diseases.

115 gic evaluation revealed no evidence of acute viral hepatitis, autoimmune, metabolic or alcohol-relate

116 ubjects died from cirrhosis; 33 of them from viral hepatitis B (29%), two from hepatitis C (2%), and

117 Data on viral hepatitis B (HBV) testing and vaccination in prima

118 527 adult participants who were negative for viral hepatitis B and C and iron overload.

119 Viral hepatitis B and C are among the most common causes

120 osis and management of patients with chronic viral hepatitis B and C depend on the amount and progres

121 on of "normal liver function tests." Chronic viral hepatitis B and C remain important risk factors fo

122 1988-1994, who were negative for markers of viral hepatitis B and C.

123 that unify HCC occurring in a background of viral hepatitis B and C.

124 Randomisation was stratified by viral hepatitis B or C coinfection and computer-generate

125 been implicated in protecting patients with viral hepatitis B or C from developing hepatocellular ca

126 methods used to manage patients with chronic viral hepatitis B or C infection.

127 titis (FCH) is a rapidly progressive form of viral hepatitis B that occurs in severely immunosuppress

128 elopments in the treatment and prevention of viral hepatitis based on publications between December 2

129 eview of recent developments in the field of viral hepatitis, based on publications between December

130 eview of recent developments in the field of viral hepatitis, based on publications between December

131 eview of recent developments in the field of viral hepatitis, based on publications between December

132 llular carcinoma among patients with chronic viral hepatitis been prospectively evaluated in a low-ri

133 llular carcinoma among patients with chronic viral hepatitis, but it is not a prerequisite for liver

134 s liver injury and increases the severity of viral hepatitis, but the precise mechanisms responsible

135 HO adopted a strategy for the elimination of viral hepatitis by 2030.

136 and for cirrhosis and liver cancer caused by viral hepatitis, by age, sex, and country from 1990 to 2

137 e of antiviral treatment options for chronic viral hepatitis C (CHC), shared clinical decision-making

138 Viral hepatitis C (HCV), a small (+)-RNA virus, infects

139 Pathologic features of viral hepatitis C and E, immunohistochemistry for the du

140 We have demonstrated that the viral hepatitis C IRES element is a powerful mediator of

141 miR-122, a pro-viral hepatitis C virus (HCV) host factor, binds and rec

142 ibrosis extent, including cause of fibrosis (viral hepatitis C vs nonalcoholic fatty liver disease, P

143 operational interventions along the chronic viral hepatitis care continuum, published in English up

144 e engagement and retention along the chronic viral hepatitis care continuum.

145 Viral hepatitis cases reported to the NYC Department of

146 During development of chronic viral hepatitis, CCL5 and CXCL10 regulate the cytopathic

147 Division of Viral Hepatitis, Centers for Disease Control and Prevent

148 ic steatohepatitis, alcoholic liver disease, viral hepatitis, cholangiopathies, and hepatobiliary mal

149 iver disease, non-alcoholic steatohepatitis, viral hepatitis, cholestatic liver disease and autoimmun

150 on people worldwide, is the leading cause of viral hepatitis, cirrhosis and hepatocellular carcinoma.

151 nch National Agency for Research on AIDS and Viral Hepatitis CO13 HEPAVIH cohort.

152 ral hepatitis monoinfected (n = 74), and HIV-viral hepatitis coinfected (n = 66).

153 Among the HIV-infected men, viral hepatitis coinfection (2.34-FI; P < .001), HIV RNA

154 icity, ART usually is safe for patients with viral hepatitis coinfection, and, in some cases, treatme

155 tients were included, all of them related to viral hepatitis coinfection: hepatitis C virus (HCV) in

156 Etiologies of liver disease include viral hepatitis coinfections, drug-related hepatotoxicit

157 Viral hepatitis constitutes the most common entity seen

158 n-transmissible diseases, including AIDS and viral hepatitis, continue to spread especially in develo

159 uses were initially thought to cause non-A-G viral hepatitis, continued research has shown no definit

160 The WHO global health sector strategy on viral hepatitis, created in May, 2016, aims to achieve a

161 Between 1990 and 2013, global viral hepatitis deaths increased from 0.89 million (95%

162 Chronic viral hepatitis depends on the inability of the T-cell i

163 t appear to be related to recurrent disease, viral hepatitis, drug toxicity, or graft ischemia.

164 Other major advances in the field of viral hepatitis during the past year are highlighted.

165 nject drugs receive services, and a national viral hepatitis education campaign that targets health c

166 Children without viral hepatitis enrolled in 2 trials for stroke preventi

167 itis action plan that guides response to the viral hepatitis epidemic by providing explicit steps to

168 substantial portion of the global burden of viral hepatitis, especially chronic hepatitis B and hepa

169 chronic liver disease (n = 1037), defined as viral hepatitis, excessive alcohol consumption, or incre

170 efore peer-review, creating confusion in the viral hepatitis field.

171 Recurrent viral hepatitis following liver transplantation may limi

172 to the Italian Surveillance System for Acute Viral Hepatitis from 1993 to 2014.

173 the leading cause of enterically transmitted viral hepatitis globally.

174 irus (HEV) is the most common cause of acute viral hepatitis globally.

175 me from onset of injection to acquisition of viral hepatitis has increased, we also compared the find

176 Up to 30% of acute viral hepatitis has no known etiology.

177 However, the involvement of complement in viral hepatitis has not been well documented.

178 New insights into the management of viral hepatitis have been gained over the past year.

179 The livers of patients with viral hepatitis have been shown to contain elevated numb

180 iral hepatitis, sorafenib progressor without viral hepatitis, HCV infected, and HBV infected.

181 lcoholic fatty liver disease, and/or chronic viral hepatitis (hepatitis B and C), results in damage t

182 Chronic viral hepatitis (hepatitis B and hepatitis C) infection

183 habeta is the only established treatment for viral hepatitis; however, more than 60% of patients are

184 al therapies will not decrease the burden of viral hepatitis if persons at risk for or who are living

185 control group was alcohol in 16.3%, chronic viral hepatitis in 30.6%, autoimmune hepatitis in 8.2%,

186 In 2015, the Coalition to Eradicate Viral Hepatitis in Asia Pacific gathered leading hepatit

187 s associated with endemic and epidemic acute viral hepatitis in developing countries.

188 sative agent of hepatitis E, a major form of viral hepatitis in developing countries.

189 9 may have therapeutic value against chronic viral hepatitis in human patients.

190 s leading to the most severe form of chronic viral hepatitis in man.

191 e assays to identify biomarker signatures of viral hepatitis in order to define unique and common res

192 king at means of prevention and treatment of viral hepatitis in patients undergoing liver transplanta

193 itis E virus (HEV) is a major cause of acute viral hepatitis in people in many developing countries a

194 ted to assess the clinical impact of chronic viral hepatitis in the United States.

195 A causes approximately half of the cases of viral hepatitis in the United States.

196 irus (HEV) is the most common cause of acute viral hepatitis in the world.

197 particularly relevant for the development of viral hepatitis, in which both the sensitivity of hepato

198 viremia presented characteristics typical of viral hepatitis, including viral RNA and proteins in hep

199 es, the absolute burden and relative rank of viral hepatitis increased between 1990 and 2013.

200 LD deaths and the proportion attributable to viral hepatitis increased by 23% and 19%, respectively,

201 The age-adjusted death rate for non-A, non-B viral hepatitis increased from 0.4 to 1.8 deaths per 100

202 In the setting of viral hepatitis, increased expression of Gal-9 drives th

203 Viral hepatitis-induced oxidative stress accompanied by

204 fection (1.39-fold increase [FI]; P < .001), viral hepatitis infection (1.52-FI; P < .001), and the i

205 Viral hepatitis infection is a primary risk factor for H

206 Alcohol consumption and viral hepatitis infection synergistically accelerate liv

207 Viral hepatitis infection, which is a major cause of liv

208 that the association may differ by status of viral hepatitis infection.

209 th HCC have viral hepatitis; the majority of viral hepatitis infections are due to HCV.

210 ngthy follow-up, only a fraction of expected viral hepatitis infections were identified.

211 < .001), and the interaction between HIV and viral hepatitis infections were independently associated

212 ytic function and cytokine production in all viral hepatitis infections: Hepatitis virus infections d

213 s has been implicated in the pathogenesis of viral hepatitis, insulin resistance, hepatosteatosis, an

214 88-1994, with excessive alcohol consumption, viral hepatitis, iron overload, overweight, or impaired

215 Viral hepatitis is a leading cause of death and disabili

216 Tissue damage caused by viral hepatitis is a major cause of morbidity and mortal

217 Because viral hepatitis is associated with inflammation, we hypo

218 The optimal management of chronic viral hepatitis is evolving rapidly.

219 rch indicates that the mortality burden from viral hepatitis is growing, particularly among middle-ag

220 Screening for viral hepatitis is important in individuals diagnosed as

221 , an improved understanding of the burden of viral hepatitis is needed to inform global intervention

222 Viral hepatitis is still one of the most common causes o

223 Worldwide, viral hepatitis is the leading cause of acute liver fail

224 Viral hepatitis is the leading cause of liver disease wo

225 Viral hepatitis is the most common form of hepatitis and

226 of liver diseases as diverse as cholestasis, viral hepatitis, ischemia/reperfusion, liver preservatio

227 ive drug toxicity, acute cellular rejection, viral hepatitis, ischemic injury, and recurrent disease.

228 Although PG has also been reported with viral hepatitis, it is rarely associated with autoimmune

229 carcity of immunocompetent animal models for viral hepatitis, little is known about the early innate

230 HBV is a major cause of viral hepatitis, liver cirrhosis, and hepatocellular car

231 us (HCV), a Hepacivirus, is a major cause of viral hepatitis, liver cirrhosis, and hepatocellular car

232 physiology and pathophysiology, focusing on viral hepatitis, liver fibrosis, and cancer.

233 ure, and the presence of co-existing chronic viral hepatitis may increase its severity.

234 ibrosis (Meta-Analysis of Histologic Data in Viral Hepatitis [METAVIR] fibrosis stage F3) or cirrhosi

235 cted (n = 1170), HIV monoinfected (n = 509), viral hepatitis monoinfected (n = 74), and HIV-viral hep

236 Like human viral hepatitis, murine Helicobacter hepaticus infection

237 Liver disease was caused by viral hepatitis (n = 136), alcoholic or nonalcoholic ste

238 Data were analyzed from 14,841 viral hepatitis-negative adult participants in the third

239 n 18-year period (through 2006) among 14,950 viral-hepatitis-negative adults.

240 ease in the setting of HIV infection include viral hepatitis, nonalcoholic fatty liver disease/nonalc

241 operative effects of alcohol consumption and viral hepatitis on liver disease.

242 or liver transplants for diseases other than viral hepatitis or an autoimmune disease who underwent i

243 Nine patients had a history of viral hepatitis or chronic liver disease.

244 These codes do not include viral hepatitis or consider hepatocellular carcinoma (HC

245 transferase (ALT) activity in the absence of viral hepatitis or excessive alcohol consumption is most

246 levated serum ALT activity in the absence of viral hepatitis or excessive alcohol consumption, most o

247 Among participants without viral hepatitis or excessive alcohol consumption, those

248 higher FRS among nonobese participants with viral hepatitis or excessive alcohol consumption.

249 ng coincidental liver disease (most commonly viral hepatitis or gallstones) and underlying chronic li

250 do not have evidence of the risk factors of viral hepatitis or heavy alcohol consumption.

251 Of cases for which viral hepatitis or hepatobiliary cancer was the cause of

252 ent who developed hepatitis had a history of viral hepatitis or liver disease, and none had been prev

253 ths while receiving ART, and without chronic viral hepatitis or other known causes of chronic liver d

254 Acute liver failure caused by viral hepatitis or toxic damage involves both apoptotic

255 that included death certificates where CLD, viral hepatitis, or CLD-related sequelae were reported a

256 k is independent of alcoholic liver disease, viral hepatitis, or demographic features.

257 -defining malignancy, chronic liver disease, viral hepatitis, overdose, obstructive lung disease, cor

258 he substantial US health burden from chronic viral hepatitis, particularly among persons born during

259 have been mostly performed in the setting of viral hepatitis, particularly hepatitis C virus, where s

260 This study highlights the importance of viral hepatitis prevention and treatment and HCC screeni

261 This article highlights recent advances in viral hepatitis published from December 2003 to November

262 val, Epstein-Barr virus (EBV) occurrence, or viral hepatitis recurrence.

263 evels are increased in patients with chronic viral hepatitis, reflecting macrophage activation.

264 quent causes of death among decedents with a viral hepatitis-related death.

265 Patients with curative resection of viral hepatitis-related HCC were eligible, and were stra

266 d not reduce the postoperative recurrence of viral hepatitis-related HCC.

267 thin the French National Agency for AIDS and Viral Hepatitis Research (ANRS) 12249 Treatment as Preve

268 the French National Agency for HIV/AIDS and Viral Hepatitis Research 12 180 Reflate Tuberculosis tri

269 Acute viral hepatitis resulting due to hepatitis E viral infec

270 We analyzed liver function studies, viral hepatitis screening tests, quantitative polymerase

271 improved HBV vaccine coverage; and improved viral hepatitis services and access to those services.

272 Effective management for viral hepatitis should be integrated into HIV treatment

273 sets, a New World small primate, and induces viral hepatitis similar to HCV infection in humans.

274 s: sorafenib untreated or intolerant without viral hepatitis, sorafenib progressor without viral hepa

275 vival for persons with HCC differs widely by viral hepatitis status.

276 Men were categorized based on their HIV and viral hepatitis status: uninfected (n = 1170), HIV monoi

277 A comprehensive approach involving better viral hepatitis surveillance and case investigation, hea

278 ree health departments that perform enhanced viral hepatitis surveillance in New York and Oregon.

279 uency of and characteristics associated with viral hepatitis testing and infection prevalence among a

280 Little is known about viral hepatitis testing and infection prevalence among p

281 operational interventions to enhance chronic viral hepatitis testing, linkage to care, treatment upta

282 accelerates liver fibrosis in patients with viral hepatitis that cannot be fully explained by ethano

283 le discusses over 40 studies in the field of viral hepatitis that were published in 2003.

284 ysis was performed on e-mail inquiries about viral hepatitis that were submitted by health profession

285 In NYC, most persons with HCC have viral hepatitis; the majority of viral hepatitis infecti

286 The national viral hepatitis therapy program has significantly reduce

287 A national viral hepatitis therapy program was launched in Taiwan i

288 in therapeutic strategies for patients with viral hepatitis, there is a significant lack of novel th

289 y may be more common in persons with chronic viral hepatitis, these data do not support withholding p

290 afforded basic levels of protection against viral hepatitis transmission.

291 model for investigating the pathogenesis of viral hepatitis types A through E in humans.

292 Precipitating events may be viral hepatitis, typically in Asia, and drug or alcoholi

293 Patients with acute viral hepatitis underwent antibody testing for other cau

294 splantation is in danger of being overrun by viral hepatitis, unless effective strategies can be used

295 Infection with viral hepatitis was associated with increased frequencie

296 In 2013, viral hepatitis was the seventh (95% UI seventh to eight

297 Using a mouse model of viral hepatitis, we identified virus-induced early trans

298 dents would be useful for the study of human viral hepatitis, where it might allow the species, techn

299 of the patients had underlying cirrhosis or viral hepatitis, which is commonly seen in adults with H

300 Livers from patients with viral hepatitis without and with HCC (n = 114) were exam